1 / 1

RESULTS Stage I-II

Incidence of lung cancer in Europe cases/100.000 males. cumulative survival. cumulative survival. Role of (18)FDG-PET/CT and SUV evaluation in the management of Non-Small Cell Lung Cancer in different stages. A. Cistaro 1 , N. Q uartuccio 2 , M.A. Rimicci 2 , P. Fania 1 , U. Ficola 2.

khuyen
Download Presentation

RESULTS Stage I-II

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Incidence of lung cancer in Europe cases/100.000 males cumulative survival cumulative survival Role of (18)FDG-PET/CT and SUV evaluation in the management of Non-Small Cell Lung Cancer in different stages A. Cistaro1,N.Quartuccio2, M.A. Rimicci2, P. Fania1, U. Ficola2 1 Positron Emission Tomography Center IRMET S.p.A., Turin, Italy 2 Nuclear Medicine Dept. “La Maddalena” Hospital, Palermo, Italy • PURPOSES • To evaluate the correlation between SUVmax and clinical outcome in two different groups of patients: • patients with NSCLC in stage I-II undergoing surgery; • patients with NSCLC in stage III-IV undergoing chemotherapy MATHERIALS AND METODS - 135 patients (49 stage I-II, 86 stage III-IV), underwent 2 (18)FDG-PET whole body. - SUVmax and dimension of the lesion were recorded. - In the group of patients in stage I-II SUVmax and clinical outcome were put in relationship by Student-t test, and the optimal cut-off value of SUVmax to predict prognosis was calculated. The probability of Disease-Free Survival was investigated through the univariate analysis of Kaplan-Meier. - In the group of stage III-IV patients we looked for a possible correlation between SUVmax and best response, and for the most significant cut-off value of SUVmax to predict prognosis. RESULTS Stage I-II Mean SUVmax: 8,96 Diam medium: 32,27 mm A: Disease-free: 35 pts 49 pts SUVmax medium:10 Diam med: 33mm Mean SUVmax: 12,8 Diam medium: 40,5 mm B: Disease relapse:13pts RESULTS Stage III-IV Population of patients in stage III-IV presented a mean SUVmax of 12,5 and the average diameter of the primitive lesions was42 m. The patients, were classified in : - 22 PD(progressive disease), - 33 PR(partial response), - 24 SD(stable disease), - 7 RC (complete response). Patients were then divided in two groups according to the follow-up: - Group P: patients with progressive disease (PD): 22, average SUVmax11,8(SD: 5,23), medium diameter of primitive lesion 43,35 mm (SD: 16,63). - Group C: patient with disease under control [(PR), (SD), (RC)]: 64, average SUVmax value12,7 (SD: 8,05) and medium diameter of primitive lesion 41,6 mm (SD: 21,15). CONCLUSIONS Stage I-II patients with SUVmax>9 (cut-off value)and diameter of lesion>30mm (cut-off value) reported the worst prognosis. An important correlation exists between responses according to CT and FDG-PET. In stages III and IV, no reliable cut-off value of SUVmax was found in correlation with prognosis and response to therapy.

More Related